Abstract
Tuberculosis (TB) is one of the most devastating diseases primarily due to several decades of neglect, and presents a global health threat of escalating proportions. TB is the second leading infectious cause of mortality today behind only HIV/AIDS. The impetus for developing new structural classes of anti-tuberculosis drugs comes from the emergence of multi-drug resistant (MDR) strains to commonly used drugs, substantially longer durations of therapy that are needed as a result of resistance, and the resurgence of disease in immunocompromised patients. Recent years have witnessed emergence of many new structural classes of anti-TB agents, which have exhibited promising activities against drug-sensitive and drug-resistant strains of the causative organism Mycobacterium tuberculosis. These analogs ideally should decrease the overall duration of therapy with improved efficacy, and exhibit mechanisms of action different from those of existing drugs to counter the resistant strains of M. tuberculosis. This review provides a comprehensive literature compilation on advances in the new structural classes of anti-TB analogs reported during the past five years. Our discussion and observations are concentrated on chemotherapeutic potential of alphabetically listed twenty-seven new structural classes of anti-tuberculosis agents that include:- acetamides, 5-arylidene-2-thiohydantoins, benzoxazoles and benzothiazoles, benzoic acid hydrazones, benzoxazines, carbohydrates, chalcones, coumarins, deazapteridines, imidazoles, indoloquinazolinones, isothiosemicarbazones, mycobactins, 1,8- naphthyridines, phenazines, purines, pyridines, N-pyridinylsalicylamides, pyrimidines and thymidines, pyrroles, quinolines, quinoxalines, terpenes, thiadiazine thiones, thiolactomycines, toludines, and triazoles.
Keywords: tuberculosis (tb), mycobacterium tuberculosis, vaccine, acetamides, benzoxazoles, qsar, carbohydrates
Current Medicinal Chemistry
Title: Recent Advances in New Structural Classes of Anti-Tuberculosis Agents
Volume: 12 Issue: 16
Author(s): Amit Nayyar and Rahul Jain
Affiliation:
Keywords: tuberculosis (tb), mycobacterium tuberculosis, vaccine, acetamides, benzoxazoles, qsar, carbohydrates
Abstract: Tuberculosis (TB) is one of the most devastating diseases primarily due to several decades of neglect, and presents a global health threat of escalating proportions. TB is the second leading infectious cause of mortality today behind only HIV/AIDS. The impetus for developing new structural classes of anti-tuberculosis drugs comes from the emergence of multi-drug resistant (MDR) strains to commonly used drugs, substantially longer durations of therapy that are needed as a result of resistance, and the resurgence of disease in immunocompromised patients. Recent years have witnessed emergence of many new structural classes of anti-TB agents, which have exhibited promising activities against drug-sensitive and drug-resistant strains of the causative organism Mycobacterium tuberculosis. These analogs ideally should decrease the overall duration of therapy with improved efficacy, and exhibit mechanisms of action different from those of existing drugs to counter the resistant strains of M. tuberculosis. This review provides a comprehensive literature compilation on advances in the new structural classes of anti-TB analogs reported during the past five years. Our discussion and observations are concentrated on chemotherapeutic potential of alphabetically listed twenty-seven new structural classes of anti-tuberculosis agents that include:- acetamides, 5-arylidene-2-thiohydantoins, benzoxazoles and benzothiazoles, benzoic acid hydrazones, benzoxazines, carbohydrates, chalcones, coumarins, deazapteridines, imidazoles, indoloquinazolinones, isothiosemicarbazones, mycobactins, 1,8- naphthyridines, phenazines, purines, pyridines, N-pyridinylsalicylamides, pyrimidines and thymidines, pyrroles, quinolines, quinoxalines, terpenes, thiadiazine thiones, thiolactomycines, toludines, and triazoles.
Export Options
About this article
Cite this article as:
Nayyar Amit and Jain Rahul, Recent Advances in New Structural Classes of Anti-Tuberculosis Agents, Current Medicinal Chemistry 2005; 12 (16) . https://dx.doi.org/10.2174/0929867054546654
DOI https://dx.doi.org/10.2174/0929867054546654 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Pleural Effusions in the Emergency Department
Reviews on Recent Clinical Trials Shikimate Kinase: A Potential Target for Development of Novel Antitubercular Agents
Current Drug Targets Study of the Scientific Production on Leishmaniasis in Latin America
Recent Patents on Anti-Infective Drug Discovery Under Performance of Anti Tuberculosis Vaccine MVA85A in BCGPrimed Subjects: A Commentary
Current Immunology Reviews (Discontinued) Chemokines in the Pathogenesis and as Therapeutical Markers and Targets of HCV Chronic Infection and HCV Extrahepatic Manifestations
Current Drug Targets Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Synthesis, Cytotoxicity, Antibacterial and Antileishmanial Activities of Imidazolidine and Hexahydropyrimidine Derivatives
Medicinal Chemistry Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Current Pharmaceutical Design Polysaccharide-synthesizing Glycosyltransferases and Carbohydrate Binding Modules: the case of Starch Synthase III
Protein & Peptide Letters Structure-Based Approaches to the Development of Novel Anti-Malarials
Current Drug Targets HIV Nef: Role in Pathogenesis and Viral Fitness
Current HIV Research Synthesis and In Vitro Antimicrobial Evaluation of 4-alkyl/aryl-1-(3-phenoxypropionyl)-thiosemicarbazides
Letters in Drug Design & Discovery Prediction and Analysis of the Protein-Protein Interaction Networks for Chickens, Cattle, Dogs, Horses and Rabbits
Current Bioinformatics Novel Electrochemical Sensor for Rifampicin based on Ionic Liquid Functionalised TiO2 Nanoparticles
Current Analytical Chemistry The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation
Current Pharmaceutical Design The Mechanism by which the Phenothiazine Thioridazine Contributes to Cure Problematic Drug-Resistant Forms of Pulmonary Tuberculosis: Recent Patents for “New Use”
Recent Patents on Anti-Infective Drug Discovery New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Current Pharmaceutical Design Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Response to HAART in Treatment-Naive HIV-Infected Patients with a Prior Diagnosis of Tuberculosis or other Opportunistic Infections
Current HIV Research Prediction of Translation Initiation Site in Bacterial and Archaeal Genomes
Current Bioinformatics